Evergreening isnt a mythbut it is easy to mythologize.
Drugmakers, payers, regulators, journalists, and investors all use the term evergreening to describe how brand companies can extend market exclusivity beyond what many people think the original pat…
The Evergreening Myth: How to Spot the Cracks in a 20-Patent Thicket Read Post »
Most people think patent litigation is about winning at the courthouse.
In pharma, thats only half the story. The other half is what happens years earlierwhen teams challenge weak or overly broad methods of use claims before they calcify into an expe…
Sue Early, Win Big: The Hidden ROI of Challenging Weak Method-of-Use Drug Patents Read Post »
The 180-Day Exclusivity Trap: Why First-to-File Winners Still Lose Money
In drug development and generic competition, the phrase first-to-file is often treated like a shortcut to value.
File first under the Hatch-Waxman framework, you win 180 days of e…
The 180-Day Exclusivity Trap: Why First-to-File Winners Still Lose Money Read Post »
ð¨ Drug patent settlements shouldnt be treated like a business as usual.
Theyre not a clean exit. Theyre a complex betoften made with imperfect information, under time pressure, and in the face of real legal and statistical uncertainty. And yet, in…
Most pharma patent fortresses dont fall because the whole wall collapsesthey fall because the weakest brick cracks first.
And in the device spacewhere courts, regulators, and litigants often ask a different set of questions than they do for traditional…
Why Device Patents Crack First: The Weakest Wall in Your Drug’s Patent Fortress Read Post »
The Salt Change Trap: When a New Patent Buys You Nothing
Drug developers love a clean headline: new patent granted. Investors love it toountil the market reality sets in.
Because in pharma, not every new patent is a new deal. Sometimes its a repackagin…
The Salt Change Trap: When a New Patent Buys You Nothing Read Post »
Pediatric exclusivity was supposed to be a safeguard: an extra six months of market protection to encourage drug developers to study children.
But in practice, the six-month fuse is too often a liabilitynot a shield.
Heres the uncomfortable reality: …
The Six-Month Fuse: Why Pediatric Exclusivity Is a Liability, Not a Shield Read Post »
Bausch Health just gave the patent world a reminder: litigation isnt only about winning argumentsits about controlling what the market believes is imminent.
The dispute at the center of the recent rulingBausch Health Companies Inc. v. Sun Pharmaceutica…
BAUSCH HEALTH COMPANIES INC. v. SUN PHARMACEUTICAL INDUSTRIES LTD. Read Post »
Exelixis v. Intas: Patents Dont Just Decide Drug FuturesThey Define Timelines, Incentives, and Who Can Afford to Wait.
Heres why this case matters beyond the courtroom.
The agitation:
When we talk about patent battles, its easy to imagine a binary outc…
Pharma news isnt just about new drugsits often about courtrooms, timing, and the fine print of patent law.
In the latest decision covered by DrugPatentWatch, Amneal Pharmaceuticals LLC v. Alembic Pharmaceuticals Ltd. is a reminder that the when of mark…
Amneal Pharmaceuticals LLC v. Alembic Pharmaceuticals Ltd. Read Post »
Get new actionable insights and updates from BiotechBlog
